These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34030548)

  • 21. Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Perales MA; Anderson LD; Jain T; Kenderian SS; Oluwole OO; Shah GL; Svoboda J; Hamadani M
    Transplant Cell Ther; 2022 Sep; 28(9):546-559. PubMed ID: 35768052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan.
    Tsutsué S; Makita S; Asou H; Matsuda H; Yamaura R; Taylor TD
    Future Oncol; 2024; 20(19):1333-1349. PubMed ID: 38597742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.
    Elmacken M; Peredo-Pinto H; Wang C; Xu Z; Tegenge M; Jaigirdar AA; Theoret MR; Purohit-Sheth T; Kasamon YL
    Clin Cancer Res; 2024 Jun; 30(11):2309-2316. PubMed ID: 38324398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
    Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
    Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
    Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023.
    Ryan CE; Jacobson CA
    Semin Hematol; 2023 Nov; 60(5):322-328. PubMed ID: 38199906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
    Patrick DL; Powers A; Jun MP; Kim Y; Garcia J; Dehner C; Maloney DG
    Blood Adv; 2021 Apr; 5(8):2245-2255. PubMed ID: 33904895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.
    Yamshon S; Gribbin C; Alhomoud M; Chokr N; Chen Z; Demetres M; Pasciolla M; Leonard J; Shore T; Martin P
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e235-e256.e2. PubMed ID: 38582666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel CAR T cell therapies for patients with large B cell lymphoma.
    Goto H; Onozawa M; Teshima T
    Int J Hematol; 2024 Jul; 120(1):6-14. PubMed ID: 38795249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
    Morschhauser F; Dahiya S; Palomba ML; Martin Garcia-Sancho A; Reguera Ortega JL; Kuruvilla J; Jäger U; Cartron G; Izutsu K; Dreyling M; Kahl B; Ghesquieres H; Ardeshna K; Goto H; Barbui AM; Abramson JS; Borchmann P; Fleury I; Mielke S; Skarbnik A; de Vos S; Kamdar M; Karmali R; Viardot A; Farazi T; Fasan O; Lymp J; Vedal M; Nishii R; Avilion A; Papuga J; Kumar J; Nastoupil LJ
    Nat Med; 2024 Aug; 30(8):2199-2207. PubMed ID: 38830991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel.
    Olson NE; Ragan SP; Reiss DJ; Thorpe J; Kim Y; Abramson JS; McCoy C; Newhall KJ; Fox BA
    Mol Cancer Ther; 2023 Mar; 22(3):406-418. PubMed ID: 36595660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma.
    Duarte C; Kamdar M
    Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390802. PubMed ID: 37098236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
    Abramson JS
    Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Next-Generation Chimeric Antigen Receptor T-cells.
    Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.
    Gordon LI; Liu FF; Braverman J; Hoda D; Ghosh N; Hamadani M; Hildebrandt GC; Peng L; Guo S; Shi L; Sehgal A
    Haematologica; 2024 Mar; 109(3):857-866. PubMed ID: 37646670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.
    Van Le H; Van Naarden Braun K; Nowakowski GS; Sermer D; Radford J; Townsend W; Ghesquieres H; Menne T; Porpaczy E; Fox CP; Schusterbauer C; Liu FF; Yue L; De Benedetti M; Hasskarl J
    Leuk Lymphoma; 2023 Mar; 64(3):573-585. PubMed ID: 36755418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma.
    Choe JH; Yu T; Abramson JS; Abou-El-Enein M
    Blood Adv; 2024 Jan; 8(2):484-496. PubMed ID: 38153350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
    Badaracco J; Gitlin M; Keating SJ
    Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
    Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
    Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.